Salarius Pharmaceuticals Launches Mid-Stage Blood Cancer Trial With Seclidemstat

Salarius Pharmaceuticals Inc SLRX has initiated an investigator-initiated Phase 1/2 trial to investigate seclidemstat as a potential treatment for hematologic cancers.
The trial will be an open-label, dose-finding, dose-expansion study to determine the maximum tolerated dose and the safety & tolerability of seclidemstat in combination with azacytidine for Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Seclidemstat is an oral, reversible inhibitor of LSD1, a key enzyme implicated in several cancer types.
Funding for the trial will be provided by MD Anderson and Salarius, with Salarius also providing seclidemstat to investigators for the clinical trial.
Price Action: SLRX shares are up 1.65% at $1.20 during the premarket session on the last check Tuesday.